LGS has previously launched more than twelve major new pharmaceutical products including: Vasotec® CHF, Prinivil®, Prinzide®, Zocor®, Primaxin® IV, Proscar®, Prilosec® DU, and Toradol® IM. 12
LGS has repositioned three major pharmaceuticals in the top U.S. selling products: Zocor, Vasotec, and Prilosec.
LGS has completed two major counter intelligence assignments: one for Primaxin and the other for Cozaar®. These both dealt with second in class new product introductions.
LGS completed an extensive marketing study analyzing the feasability of launching a new cholesterol lowering product internationally. This study involved launching a new single agent and traditional or non-traditional combinations.
LGS launched BDRX, an emesis product, for Crossing Care, LLC, in the hospice market.
LGS has launched the DNA age management neutraceutical product line for Suracell.
LGS positioned Zocor vs. Mevacor. Mevacor was positioned for primary prevention while Zocor was positioned for secondary prevention (CHD).
LGS repositioned Zocor post Lipitor to create a Hertz/Avis market.
LGS created a brand preference program for Vasotec that carried the product to sales over $1 billion.
LGS consulting handled the strategic component for a Columbia University, Department of Pediatrics, retreat on long range planning.
1 Vasotec, Prinivil, Prinzide, Zocor, Proscar, Prilosec, and Cozaar are registered trademarks of Merck & Co. Inc.
2 Toradol is a registrerd trademark of Roche Pharmaceuticals.
